J&J Acquires Experimental Eczema Drug in $1.25 Billion Cash Deal bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.
HBM Healthcare Investments AG Key word Acquisition HBM portfolio company Yellow Jersey Therapeutics to be acquired for USD 125 billion 28May2024 1401 CETCEST Release of an ad hoc announcement pursuan
(Reuters) - Johnson & Johnson said on Tuesday it had agreed to acquire the rights to an experimental skin disorder treatment from privately held Numab Therapeutics for about $1.25 billion. The drug, NM26, is currently in mid-stage development for t.
Johnson & Johnson (JNJ) announced Tuesday it has entered into a definitive agreement with biotechnology company Numab Therapeutics to acquire its wholly-owned subsidiary from Numab's shareholders in an all-cash transaction of approximately $1.